

Claire Bewshea

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2857557/publications.pdf>

Version: 2024-02-01

21
papers

1,763
citations

759233

12
h-index

794594

19
g-index

28
all docs

28
docs citations

28
times ranked

2194
citing authors

#	ARTICLE	IF	CITATIONS
1	Predictors of anti-TNF treatment failure in anti-TNF-naïve patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 341-353.	8.1	431
2	HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2020, 158, 189-199.	1.3	249
3	Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. <i>Gut</i> , 2021, 70, 1884-1893.	12.1	233
4	HLA-DQA1 and HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. <i>Nature Genetics</i> , 2014, 46, 1131-1134.	21.4	165
5	Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab. <i>Gut</i> , 2021, 70, 865-875.	12.1	153
6	Association of Genetic Variants in <i>NUDT15</i> With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 773.	7.4	129
7	COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 342-352.	8.1	100
8	Clinical Features and HLA Association of 5-Aminosalicylate (5-ASA)-induced Nephrotoxicity in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 149-158.	1.3	85
9	Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab. <i>Nature Communications</i> , 2022, 13, 1379.	12.8	48
10	Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 389-397.	1.3	39
11	Faecal calprotectin effectively excludes inflammatory bowel disease in 789 symptomatic young adults with/without alarm symptoms: a prospective UK primary care cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1103-1116.	3.7	31
12	Incidence and prevalence of inflammatory bowel disease in Devon, UK. <i>Frontline Gastroenterology</i> , 2021, 12, 461-470.	1.8	18
13	Quality improvement project identifies factors associated with delay in IBD diagnosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 471-480.	3.7	14
14	Validating the positivity thresholds of drug-tolerant anti-infliximab and anti-adalimumab antibody assays. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 128-137.	3.7	9
15	Infliximab and adalimumab are stable in whole blood clotted samples for seven days at room temperature. <i>Annals of Clinical Biochemistry</i> , 2015, 52, 672-674.	1.6	6
16	Ethical issues and best practice in clinically based genomic research: Exeter Stakeholders Meeting Report. <i>Journal of Medical Ethics</i> , 2016, 42, 695-697.	1.8	5
17	Understanding anti-TNF treatment failure: does serum triiodothyronine to thyroxine (T3/T4) ratio predict therapeutic outcome to anti-TNF therapies in biologic-naïve patients with active luminal Crohn's disease?. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 783-793.	3.7	5
18	Primary care faecal calprotectin testing in children with suspected inflammatory bowel disease: a diagnostic accuracy study. <i>Archives of Disease in Childhood</i> , 2020, 105, 957-963.	1.9	4

#	ARTICLE	IF	CITATIONS
19	OC-050...5-Aminosalicylate (5-Asa) Induced Nephrotoxicity in Inflammatory Bowel Disease. Gut, 2013, 62, A22.1-A22.	12.1	3
20	PTU-010...Prevalence and phenotype of IBD across primary and secondary care: implications for colorectal cancer surveillance. , 2018, , .		0
21	Ethical issues in genomic research: Proposing guiding principles co-produced with stakeholders. Clinical Ethics, 2018, 13, 194-198.	0.7	0